PriceTargets.com logo

Azenta - AZTA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $63.60
  • Forecasted Upside: 35.41%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$46.97 As of 12/3/2024 01:00 AM ET
▼ -0.24 (-0.51%)

This chart shows the closing price for AZTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Azenta Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZTA

Analyst Price Target is $63.60
▲ +35.41% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Azenta in the last 3 months. The average price target is $63.60, with a high forecast of $79.00 and a low forecast of $50.00. The average price target represents a 35.41% upside from the last price of $46.97.

This chart shows the closing price for AZTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Azenta. This rating has held steady since March 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024Needham & Company LLCLower TargetBuy ➝ Buy$69.00 ➝ $55.00
10/1/2024Evercore ISILower TargetIn-Line ➝ In-Line$53.00 ➝ $50.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$69.00 ➝ $69.00
7/2/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$52.00 ➝ $53.00
5/9/2024Needham & Company LLCLower TargetBuy ➝ Buy$75.00 ➝ $69.00
4/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$75.00
4/4/2024Evercore ISILower TargetIn-Line ➝ In-Line$64.00 ➝ $60.00
4/4/2024Jefferies Financial GroupInitiated CoverageHold$64.00
3/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$75.00
3/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$75.00
3/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$75.00
2/8/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$70.00
2/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$76.00 ➝ $75.00
2/1/2024B. RileyBoost TargetBuy ➝ Buy$61.00 ➝ $79.00
1/18/2024Needham & Company LLCBoost TargetBuy ➝ Buy$68.00 ➝ $76.00
11/14/2023StephensReiterated RatingEqual Weight ➝ Equal Weight$55.00
11/14/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$68.00
8/9/2023StephensBoost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $55.00
8/9/2023Needham & Company LLCBoost TargetBuy ➝ Buy$55.00 ➝ $65.00
7/18/2023Raymond JamesInitiated CoverageMarket Perform
5/10/2023Needham & Company LLCLower Target$68.00 ➝ $55.00
4/18/2023Needham & Company LLCReiterated RatingBuy$68.00
2/10/2023B. RileyLower TargetBuy$77.00 ➝ $68.00
2/9/2023Needham & Company LLCLower Target$78.00 ➝ $68.00
2/9/2023StephensDowngradeOverweight ➝ Equal Weight$65.00 ➝ $60.00
2/8/2023Needham & Company LLCReiterated RatingBuy$78.00
11/17/2022StephensBoost Target$60.00 ➝ $65.00
11/15/2022Needham & Company LLCBoost TargetBuy$74.00 ➝ $78.00
10/24/2022KeyCorpLower TargetOverweight$90.00 ➝ $70.00
8/15/2022Evercore ISILower Target$68.00
8/10/2022Needham & Company LLCLower TargetBuy$94.00 ➝ $74.00
7/14/2022B. RileyLower Target$94.00 ➝ $82.00
5/17/2022B. RileyLower Target$106.00 ➝ $94.00
5/10/2022Needham & Company LLCLower Target$115.00 ➝ $94.00
3/31/2022B. RileyInitiated CoverageBuy
3/21/2022Evercore ISIInitiated CoverageOutperform$100.00
2/9/2022Needham & Company LLCLower TargetBuy$155.00 ➝ $115.00
(Data available from 12/4/2019 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2024
  • 9 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2024
  • 9 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2024
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2024
  • 12 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2024
  • 8 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
11/4/2024
  • 17 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2024

Current Sentiment

  • 17 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Azenta logo
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $46.97
Low: $45.33
High: $47.10

50 Day Range

MA: $44.91
Low: $40.37
High: $49.38

52 Week Range

Now: $46.97
Low: $38.82
High: $69.16

Volume

585,577 shs

Average Volume

1,242,840 shs

Market Capitalization

$2.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Azenta?

The following Wall Street research analysts have issued reports on Azenta in the last twelve months: B. Riley, Evercore ISI, Jefferies Financial Group Inc., Needham & Company LLC, and Stephens.
View the latest analyst ratings for AZTA.

What is the current price target for Azenta?

0 Wall Street analysts have set twelve-month price targets for Azenta in the last year. Their average twelve-month price target is $63.60, suggesting a possible upside of 35.4%. B. Riley has the highest price target set, predicting AZTA will reach $79.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $50.00 for Azenta in the next year.
View the latest price targets for AZTA.

What is the current consensus analyst rating for Azenta?

Azenta currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AZTA, but not buy more shares or sell existing shares.
View the latest ratings for AZTA.

What other companies compete with Azenta?

Other companies that are similar to Azenta include SPX Technologies, ESAB, Moog, Weatherford International and ChampionX. Learn More about companies similar to Azenta.

How do I contact Azenta's investor relations team?

Azenta's physical mailing address is 15 Elizabeth Dr, Chelmsford, Massachusetts 01824-4111. The company's listed phone number is (978) 262-2400 and its investor relations email address is [email protected]. The official website for Azenta is www.brooks.com. Learn More about contacing Azenta investor relations.